MegaGen Implant Co., Ltd has completed the acquisition of BIOLASE, the global leader in dental laser technology, for $20 million. The deal, finalized on November 15, 2025, followed a court-supervised auction process after BIOLASE filed for Chapter 11 bankruptcy in late 2024.
From Bankruptcy to New Beginning
BIOLASE, known for its Waterlase and Epic laser systems used in over 43,000 dental practices worldwide, had been struggling financially despite strong brand recognition and a loyal clinical user base. The Chapter 11 filing in late 2024 triggered a competitive auction process in which MegaGen's bid prevailed over an initial offer from Sonendo.
Dr. Kwang Bum Park, founder of MegaGen Implant and a world-renowned implantologist, was named the new CEO of BIOLASE. Under his leadership, BIOLASE has retained its Foothill Ranch, California headquarters and its entire product portfolio, including the Waterlase iPlus (Er,Cr:YSGG all-tissue laser) and Epic X diode laser systems.
Strategic Rationale
The acquisition creates a unique combination in the dental industry: MegaGen's strength in implantology (the company holds the "Trusted Quality" mark from the German Clean Implant Foundation for nine consecutive years) combined with BIOLASE's laser expertise. The synergy is clinically logical — laser-assisted implant surgery and laser decontamination of implant surfaces are growing treatment modalities that benefit from having both technologies under one roof.
MegaGen operates in over 100 countries with 33 subsidiaries worldwide. Adding BIOLASE's distribution network and clinical training infrastructure significantly expands reach, particularly in North America where MegaGen's implant presence has been growing but lacked the brand recognition BIOLASE commands.
Product Continuity and Future Development
Existing BIOLASE customers can expect full product continuity. The Waterlase and Epic product lines remain available with enhanced service support. MegaGen has committed to increased R&D investment in laser technology and expanded clinical training programs.
The combined company is expected to launch integrated implant-laser protocols and potentially co-developed products that leverage both companies' technologies. Laser-assisted peri-implantitis treatment is an obvious first area of clinical synergy.
Market Context
The acquisition follows a broader trend of consolidation in the dental equipment industry. BIOLASE's financial struggles were not unique — several dental device companies have faced margin pressure from increasing competition and the rise of lower-cost alternatives from Asian manufacturers. MegaGen's deep pockets and global distribution network provide BIOLASE with the stability needed to invest in next-generation laser technology.
What This Means for CEE
MegaGen has an active presence in CEE dental markets, with distributors in Poland, Czech Republic, Hungary, and Romania. The addition of BIOLASE lasers to MegaGen's distribution network could significantly increase laser availability and service support in the region, where dental laser adoption has historically lagged behind Western Europe due to higher equipment costs and limited local service infrastructure.
For practices already using MegaGen implant systems, the integration of BIOLASE laser protocols could offer a compelling upgrade path for laser-assisted surgical and maintenance procedures.
FAQ
Is BIOLASE still operating? Yes. BIOLASE continues under MegaGen ownership with the same product lines, headquarters, and expanded investment in R&D and clinical training.
How much did MegaGen pay? $20 million, through a court-supervised auction following Chapter 11 proceedings. MegaGen's bid prevailed over a competing offer from Sonendo.
Will Waterlase products remain available? Yes. Full product continuity is maintained with enhanced service and training support under MegaGen's global infrastructure.
Source: PRNewswire